Beta Bionics CMO Russell sells $80,676 in company stock

Steven Jon Russell, the Chief Medical Officer of Beta Bionics, Inc., sold 4,221 shares of common stock on September 2, 2026. The shares were sold for a total of $80,676, with a weighted average price of $19.1131 per share. The sale was made to fulfill tax withholding obligations related to the vesting of restricted stock units. Following the transaction, Mr. Russell still holds 169,628 shares of Beta Bionics common stock.

Beta Bionics stock is currently trading at $19.92, marking a strong 72% return over the past six months. Despite the insider sale, the medical device company remains valued at $873 million. Beta Bionics reported a 53% revenue growth in the last twelve months, although the company remains unprofitable. InvestingPro analysis suggests that the stock is currently overvalued, placing it on the Most Overvalued list. The company offers seven exclusive tips for investors interested in BBNX.

In their latest financial results for the second quarter of 2026, Beta Bionics experienced a wider-than-expected loss of 53 cents per share, surpassing analyst expectations of a 34-cent loss. However, the company managed a 38% increase in revenue, reaching $32 million, and improved its gross margin. Beta Bionics reaffirmed its full-year outlook, expressing confidence in its future performance.

Analyst William Blair initiated coverage on Beta Bionics with a Market Perform rating, praising the company's unique AID algorithm on the iLet insulin pump.